Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
Drug-Receptor Interactions01:29

Drug-Receptor Interactions

Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognostic Reclassification and Survival Outcomes in Intermediate-Risk and Poor-Risk Nonseminomatous Germ Cell Tumors: Single-Institution Experience From Western India.

JCO global oncology·2026
Same author

Unveiling the variations in penile cancer care: identifying knowledge gaps and research priorities.

BMJ oncology·2026
Same author

Bladder Adjuvant Radiotherapy: Phase III Multicenter Randomized Controlled Trial of Adjuvant Radiotherapy or Observation for Postcystectomy Muscle-Invasive Bladder Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Prognostic Factors in Oropharyngeal Cancer Treated With Definitive Chemoradiotherapy.

Cancer medicine·2026
Same author

Pattern of resistance on first-line EGFR-directed therapy in EGFR-positive metastatic NSCLC.

Ecancermedicalscience·2026
Same author

Contemporary management of adrenocortical carcinoma: A narrative review.

Urologic oncology·2026

Related Experiment Video

Updated: Jul 2, 2026

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

Polyvalency: a promising strategy for drug design.

David Vance1, Mrinal Shah, Amit Joshi

  • 1The Howard P. Isermann Department of Chemical and Biological Engineering, Rensselaer Polytechnic Institute, 110, 8th Street, Ricketts Building, Troy, New York 12180, USA.

Biotechnology and Bioengineering
|August 30, 2008
PubMed
Summary

Polyvalent inhibitors, which bind multiple targets simultaneously, offer enhanced affinity. This study designs potent polyvalent molecules to neutralize anthrax toxin, exploring structure-activity relationships for future drug development.

More Related Videos

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

Related Experiment Videos

Last Updated: Jul 2, 2026

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Drug Design

Background:

  • Simultaneous binding of multiple ligands to multiple receptors enhances affinity compared to single ligand-receptor interactions.
  • This principle of polyvalency can be leveraged to create effective inhibitors of toxins and pathogens.

Purpose of the Study:

  • To design potent polyvalent inhibitors capable of neutralizing anthrax toxin in vivo.
  • To investigate the relationship between the structural characteristics of these inhibitors and their biological activity.

Main Methods:

  • Design and synthesis of polyvalent inhibitor molecules.
  • In vivo testing of inhibitor efficacy against anthrax toxin.
  • Structure-activity relationship (SAR) analysis.

Main Results:

  • Successful design of potent polyvalent inhibitors that neutralize anthrax toxin in vivo.
  • Elucidation of key structural features contributing to inhibitor potency and efficacy.

Conclusions:

  • Polyvalent drug design is a promising strategy for developing potent inhibitors against toxins like anthrax.
  • Further research into polyvalent inhibitors holds potential for novel therapeutic applications.